Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-744-1 | CAS number: 2885-00-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
- Justification for type of information:
- Results are based on octanethiol which is a shorter alkyl chain version of octadecylmercaptan. As the thiol/mercaptan group is the active functional group then any toxic effects will specifically be due to the terminal thiol/mercaptan group. The alkyl chain just affects the water solubility and does not play a significant biochemical role or toxicological role. That is why the C8 thiol is a very good analogue for the longer chain thiol/mercaptan.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Report date:
- 2000
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- GLP compliance:
- not specified
- Limit test:
- yes
Test material
- Reference substance name:
- Octane-1-thiol
- EC Number:
- 203-918-1
- EC Name:
- Octane-1-thiol
- Cas Number:
- 111-88-6
- Molecular formula:
- C8H18S
- IUPAC Name:
- octane-1-thiol
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Rearing automatically controlled at a temperature of 22 ± 2 ° C., relative humidity of 55 ± 15%, ventilation at about 12 times / hour, lighting 12 hours / day (7: 00-19: 00) I used.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- Daily exposure for 35 days total.
- Frequency of treatment:
- Daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 50 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 125 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 250 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 3 males and 3 females per dose.
- Control animals:
- yes, concurrent vehicle
Examinations
- Observations and examinations performed and frequency:
- Observations made at 0, 3, 7, 14, 21, 28 and 34 days test duration for males
Observations made at 0, 3, 7, 14 prior to mating; 0, 7, 14, 20 gestation period and 0, 4 days lactation period for females - Sacrifice and pathology:
- On the 35th day
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Adverse effects were observed at the 250mg'kg bw dosage which were consistent with changes in organ weight, blood changes, ulceration and thickening of the forestomach and reddening of the spleen.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Mortality occurred for the 500mg/kg bw for 1 male and 1 female after 14 days dosing.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Effects on body weight gain were suppressed at and above 125mg/kg bw administration
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Decreased food intake was observed at administration at and above 125mg/kg bw.
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- Water consumption was twice as high as that of the control group in the 250mg/kg bw group.
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Enhanced haematopoiesis and hemosiderin deposition.
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- For all males and females, blood collected on the day of dissection was left to stand at room temperature for about 30 minutes and then centrifuged. GOT and GPT (UV-rate method (JSCC improved method)), γGT (γ ALP (ρ-nitrophenyl phosphate substrate method (JSCC modified method)), total bilirubin (enzyme method (BOD method)), urea nitrogen (enzyme-UV (Enzyme method - UV method (HK - G 6 PDH method)), Total cholesterol (Enzyme method (CO - HDAOS method)), Triglyceride (Urease - LEDH method), Creatinine (Creatininase - POD method), Glucose Total protein (Biuret method), albumin (BCG method), A / G ratio (calculated from total protein and albumin), calcium (OCPC method), inorganic phosphorus (GPCO-HDAOS method, glycerin elimination method) Enzymatic method (PNP-XOD-POD method)), sodium, potassium and crawl (ion selective electrode method) were measured using an automatic analyzer (TBA-200FR, Toshiba).
- Urinalysis findings:
- effects observed, treatment-related
- Description (incidence and severity):
- 6 fresh urine of each dose group was collected before administration on the 33rd day after administration, and pH, protein, glucose, ketone bilirubin, occult blood, occult blood, urobilinogen (test paper method, Martistic: Bayer Medical) were automatically urine Urinary sediment (Sternheimer-Malbin stained specimen) was examined by measurement with an analyzer (Clinitec 100, Bayer Medical). The urine volume was measured using stored urine for about 21 hours and the specific gravity (refraction method) was measured using a urine gravimeter (Yuricon-JE, Atago), sodium potassium (ion selective electrode method), crawl (coulometric titration method) Was measured.
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- On the organ weight, high values of spleen, liver and kidney weight and low value of thymus weight were observed in males and females of 250 mg / kg group.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Changes that seemed to be caused by the test substance were found in femoral bone marrow, spleen, thymus, male femoral bone marrow, liver and female adrenal glands and lungs in males and females.
In the forestomach, erosion or ulcer, hyperplasia of squamous epithelium, hyperkeratosis, edema of submucosal tissue, inflammatory cell infiltration was observed in the group of 50 mg / kg or more, and in the 250 mg / kg group it was changed Significant enhancement was observed.
Erythroid extramedullary hematopoiesis in the spleen was significantly enhanced in males and females of the 250 mg / kg group, and congestion was also observed in the same group. In addition, hemosiderin deposition was observed in all sexes of the 250 mg / kg group, which was significantly increased compared to the control group. Hemosiderin was confirmed by blue staining with Berlin Blue stain.
Atrophy of the thymus was observed in males and females of the 250 mg / kg group. The same change was observed in females in the control group, but the expression number increased in the 250 mg / kg group, and therefore it was judged as the influence of the test substance.
An increase in erythroid hematopoietic cells in the femoral bone marrow and a hepatic central lobular hepatocyte hypertrophy were found in males in the 250 mg / kg group and hypertrophy of the adrenal cortical bundle band cells was observed in females of the 250 mg / kg group .
Collected lung foam cells were found in one female of 50 mg / kg group and three females of 250 mg / kg group.
Moderate diffuse seminiferous tubule atrophy in the testes was found only on one side of the 3 males in the 250 mg / kg group, of which 2 cases showed atrophy in the ipsilateral epididymis and the remaining one in the side testicles The upper body was missing. However, the contralateral testicle only had normal or mild localized seminiferous atrophy.
One female in the control group that did not copulate showed spleen granulomatous inflammation, peritoneal inflammatory cell infiltration, inflammatory cell infiltration of the tibia. - Neuropathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- no effects observed
Effect levels
open allclose all
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- >= 10 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- gross pathology
- haematology
- organ weights and organ / body weight ratios
- urinalysis
- water consumption and compound intake
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 50 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- food efficiency
- gross pathology
- haematology
- organ weights and organ / body weight ratios
- urinalysis
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
- Lowest effective dose / conc.:
- 10 mg/kg bw/day (actual dose received)
- System:
- gastrointestinal tract
- Organ:
- stomach
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.